The “psychedelic drug” label appears to define a clear-cut category. However, there are lesser-known research chemicals that depict more diffuse boundaries in this classification.
Research is indicating that a less efficient metabolic pathway plays a role in DMT’s psychoactivity.
Morris has insightful ideas for studying psychedelic toad secretions while prioritizing the conservation of toads.
GPCRs play a major role in the psychedelic effect. They also have qualities that make them ideal targets for drug development.
Understanding the potency of the compounds in nature’s cocktails is essential for formulating effective doses.
Hofmann’s work with LSD started with purpose, faded away, and then went down in history.
In 2020, the path forward for psychedelic drug research goes in several directions.
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
The 5-HT2A receptor is central to the effects of many psychedelics, but it may not be the only receptor involved.
A recent Nature paper provides novel insights into the neural correlates of the Breakthrough Experience associated with DMT.